New specification for steviol glycoside under evaluation by FSANZ
Australia
Aug 30, 2021
FSANZ is evaluating approval of a new specification for the steviol glycoside, rebaudioside I, produced by enzymatic bioconversion of stevia leaf extract. Bioconversion enzymes are derived from a genetically modified yeast strain, Pichia pastoris.
For further information (in English), click on the Link
Tags:
Nigeria/USA - Navigating regulatory challenges and safety considerations in lactation supplement development: A Nigeria and US Comparison
Nigeria
Apr 17, 2024
New rules for dietary supplements handling companies in Michigan
USA
Apr 12, 2024
FDA warns about toxic yellow oleander in dietary supplements
USA
Apr 11, 2024
Algae list added to Germany's substances list
European Union
Apr 11, 2024
FDA Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements
USA
Apr 08, 2024
ANVISA updates regulation on food supplements
Brazil
Mar 08, 2024
TGA updates list of permissible ingredients in Therapeutic Goods
Australia
Mar 08, 2024
FDA new guidance on "New Dietary Ingredient Notification Procedures and Timeframes"
USA
Mar 03, 2024
ANVISA revises pre-market control system
Brazil
Feb 28, 2024
FDA updates directory of ingredients used in dietary supplements
USA
Feb 21, 2024
USA - A Review of Probiotic Ingredient Safety Supporting Monograph Development Conducted by the United States Pharmacopeia (USP)
USA
Feb 19, 2024
Published update to regulation on dietary supplements
Ukraine
Feb 12, 2024
New Draft Regulation on Dietary Supplements
Uruguay
Feb 05, 2024
Proposal to repeal the Law on Dietary Supplements
Peru
Jan 26, 2024
Trimagnesium dicitrate (E 345(i)) authorized as additive in food supplements
European Union
Jan 24, 2024